*4.2.2.1 Etomidate*

Etomidate has minimal effects on hemodynamics, therefore, it is considered for use, particularly in elderly, critically ill, and/or hemodynamically unstable patients. Due to its inhibition of the adrenal cortex, etomidate is not recommended for immunosuppressed or septic patients. Very few studies have investigated the effect of etomidate on cancer. In an in vivo study by Liu et al. [34] in 2016, it was found that etomidate significantly reduces the viability of macrophages in a dose-dependent manner.
